Norwest Venture and 22C Capital-backed-Target RWE completed the acquisition of NoviSci.

Norwest Venture and 22C Capital-backed-Target RWE, a real-world evidence solutions company, completed the acquisition of NoviSci, a biotechnology company. Amgen, a strategic investor in and collaborator with NoviSci, has also made a strategic investment in the combined company to fuel growth. Financial terms were not disclosed. “Target RWE’s proven real-world data and evidence solutions continue to grow in breadth, depth and value for our research and industry partners. With the addition of NoviSci’s novel analytics platform and experienced team, Target provides a highly adaptive environment to accelerate insights and reproducible research output from real-world data to various stakeholders in the healthcare ecosystem, including our pharmaceutical industry partners, healthcare investigator partners, government agencies and payor organizations," Neal Bibeau, Target RWE CEO.